| ¡@ |
|
PACK-LINK BioVentures
participated in Bayhill
Therapeutics Inc. Series B
private venture financing. |
|
04/15/2005 |
|
|
PACK-LINK BioVentures
participated in Bayhill
Therapeutics Inc. Series B
private venture financing of
$35.4 million led by De Novo
Ventures and Lilly Ventures and
joined by Series A shareholders,
CMEA Ventures, Latterell Venture
Partners, Morgenthaler Ventures,
U.S. Venture Partners, and the
Vertical Group. Participants in
this new round of financing
include A.M. Pappas Life Science
Ventures; Boston Life Science
Venture Corp (Taiwan); Grand
Cathay Venture Capital Company,
LTD (Taiwan); Montreux Equity
Partners; PAC-LINK Bio
Management Corp (Taiwan);
Prudence Venture Investment Corp
(Taiwan); and Quintiles'
PharmaBio Development.
Bayhill Therapeutics Inc. is
focused on the translation of
research into therapeutics by
developing novel drugs for the
treatment of autoimmune
diseases. The company has
established a therapeutic
platform of antigen specific
therapeutics, BHT-DNA?, with
broad potential applications in
treating autoimmune diseases,
including multiple sclerosis,
type 1 diabetes, and rheumatoid
arthritis.¡@ |
| ¡@ |
¡@ |
¡@ |
